
Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript
Passage Bio, Inc., a genetic drug company, develops transformative therapies for rare monogenic central nervous system (CNS) diseases. The company is headquartered in Philadelphia, Pennsylvania.
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-37.55M |
| Operating Margin | 0.00% |
| Return on Equity | -128.90% |
| Return on Assets | -39.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $3.66 |
| Price-to-Book | 1.24 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.87 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $3.21M |
| Float | $2.89M |
| % Insiders | 7.72% |
| % Institutions | 60.32% |
Volatility is currently contracting

Passage Bio, Inc. (PASG) M&A Call Prepared Remarks Transcript

Combined company to operate as Remix Therapeutics and advance Remix's pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin

PBFT02 administration resulted in improvements in two disease progression biomarkers, as compared to natural history, reducing brain atrophy and stabilizing plasma NfL levels
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on PASG and any ticker you trade — then tracks every position and per-strategy win rate.